key: cord-0862617-l8krz7db
authors: Basavaraja, Chetak Kadabasal; Sebastian, Juny; Ravi, Mandyam Dhati; John, Sheba Baby
title: Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India
date: 2021-11-22
journal: Ther Adv Vaccines Immunother
DOI: 10.1177/25151355211055833
sha: 310273e5f910f81bf236aeee9c8a2b0cbc7bf15b
doc_id: 862617
cord_uid: l8krz7db

BACKGROUND: The COVID-19 vaccination program was introduced in India on 16 January 2021. The Government-issued fact sheet was the only source of information regarding Adverse Events Following Immunizations (AEFIs) for these vaccines. The objective of this study was to assess the AEFIs reported following COVID-19 vaccination in a tertiary care teaching hospital. MATERIALS AND METHODS: The spontaneous reporting method was used for data collection for a period of 3 months. A data collection form was designed to collect the data from the study population who reported adverse events. Collected data were analyzed and categorized by severity and seriousness. The causality assessment team performed causality assessment of the AEFIs using the World Health Organization’s causality assessment algorithm. RESULTS: A total of 11,656 doses of COVID-19 vaccine were administered at the study site during the study period, of which 9292 doses were COVISHIELD™ and 2364 doses were COVAXIN™. In all, 445 AEFIs were reported from 269 subjects with an incidence rate of 3.48%. The majority of the subjects with AEFIs belonged to the age group of 18–45 years. Out of the total 445 AEFIs, 418 AEFIs were expected as per the fact sheets, 409 with COVISHIELD™ and 9 with COVAXIN™. Most of the AEFIs [62.02% (n = 276)] were observed at the system organ class of ‘General disorders and administration site conditions’. After the causality assessment, out of 433 AEFIs to COVISHIELD(TM) vaccine, 94.22% (n = 408) of events were categorized to have ‘consistent causal association with immunization’. Out of 12 adverse events following COVAXIN™, 8 (66.66%) events were categorized as ‘consistent causal association with immunization’. All of them recovered from their adverse events without any sequelae. CONCLUSION: Spontaneous reporting is one of the cheapest methods that can be used for the reporting of AEFI. This method helps health care professionals to identify rare events and potential signals.

More than one-third of the global population underwent some form of lockdown and curfew because of this pandemic. The Government of India also took steps toward controlling the pandemic by a nationwide lockdown from 25 March 2020, restricting the movement of its 1.3 billion citizens. The lockdown was extended until the end of May. Subsequently, unlocking was initiated in a phased manner from 1 June 2020. 4 On 30 January 2020, India's first novel coronavirus patient was identified in South India, and by April 2021, more than 1.35 crore COVID-19confirmed cases have been reported. 5 The development of a vaccine generally takes an average of 10-15 years. 6 However, different public organizations, regulatory agencies, and pharmaceutical companies worked together to develop COVID-19 vaccines rapidly by a scientific approach. Knowledge gained through the past research on other diseases such as severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) caused by viruses of the same Corona family helped scientists to accelerate the development of new vaccines for the current COVID-19 pandemic. During the development process of vaccines, no clinical trial phases were skipped, but the phases were overlapped to speed up the process so that the vaccines could be made available to the public as soon as possible. 7, 8 The Government of India constituted the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) to oversee all aspects of the introduction of the COVID-19 vaccine in India. Two vaccines that were approved for restricted use in an emergency situation by the Central Drugs Standard Control Organisation (CDSCO) in India are COVISHIELD™ (AstraZeneca's vaccine manufactured by Serum Institute of India) and COVAXIN™ (manufactured by Bharat Biotech Limited). [9] [10] [11] Comparison of both COVISHIELD™ and COVAXIN™ is given in Table 1 .

Vaccination campaigns for COVISHIELD™ and COVAXIN™ were started in India on 16 January 2021 for all health care professionals and frontline workers. Vaccination drive for citizens aged above 60 years started on 1 March 2021 and later included citizens aged above 45 years with comorbidities. By 1 April 2021, the program was expanded to include all those aged 45 years and above even without comorbidities. [12] [13] [14] [15] Vaccination program with COVISHIELD™ was started on 16 January 2021 itself at the study site and COVAXIN™ was subsequently added to the vaccination program from 13 March 2021.

An Adverse Event Following Immunization (AEFI) is any untoward medical occurrence that follows immunization and which does not necessarily have a causal relationship with the usage of the vaccine. Operational guidelines of COVID-19 vaccines clearly specify everything including the process of monitoring, reporting, and management of AEFIs. The possible AEFIs following both the vaccines are given in the vaccine fact sheet (Table 1) . 10, 11 As per the operational guidelines, each beneficiary needs to be observed at the immunization center for a minimum of 30 min for AEFIs or adverse events (AEs) of special interest (AESIs). After 30 min, the beneficiaries are free to report the development of any AEs to the vaccination center whenever they develop any. 16 This study was conducted with an objective to assess the AEs following COVID-19 vaccinations at the study site.

The study site is a tertiary care teaching hospital having an adverse drug reaction-monitoring center (AMC) under the Pharmacovigilance Program of India (PvPI). Both active and passive surveillance for AEFIs have been instituted in this site for the past 9 years. Study process: The study population was observed for a period of 30 min following vaccination at the Immunization center. Posters of the possible AEFIs were made available in the Vaccination series is two doses given 4 weeks apart with a dose of 0.5 ml each

The vaccine will be given as an intramuscular (IM) injection only, preferably in the deltoid muscle

The vaccine will be given as an injection into the deltoid muscle of the upper arm Figure 1 .

The number of subjects who reported AE was 269 and the calculated incidence rate of AEs following COVID-19 vaccination was 3.48% (total number of subjects who developed AEFIs/total number of beneficiaries × 100). The incidence rate of AEs following COVISHIELD™ was 4.32% and following COVAXIN™ was 0.57%. Females (n = 198) developed more AEFIs when compared with males (n = 71). In all, 22.67% of the study population developed AEFIs during the observation period following the vaccination, of which 53 AEFIs were to COVISHIELD™ and 8 to COVAXIN™. The majority of the study population with AEFIs belong to the age group of 18-45 years (82.53%, n = 222) followed by 46-60 years (6.32%, n = 17) and above 60 years (11.15%, n = 30). Table 4 .

A total of 20 beneficiaries who developed AEFIs had comorbid conditions and all of them received the COVISHIELD™ vaccine. The comorbid conditions observed were diabetes + hypertension (n = 10), hypothyroidism 

AEFI, Adverse Events Following Immunization. a AEFI reaction that occurred from fact sheet for COVAXIN™ (1st dose) = 8, AEFI reaction that occurred from other than fact sheet for COVAXIN™ (1st dose) = 3, Total = 11 AEFIs. b AEFI reaction that occurred from fact sheet for COVAXIN™ (2nd dose) = 1, AEFI reaction that occurred from other than fact sheet for COVAXIN™ (2nd dose) = 0, Total = 1 AEFI. 

AEFI, Adverse Events Following Immunization. a AEFI reaction that occurred from fact sheet for COVISHIELD™ (1st dose) = 402, AEFI reaction that occurred from other than fact sheet for COVISHIELD™ (1st dose) = 24; Total = 426 AEFIs. b AEFI reaction that occurred from fact sheet for COVISHIELD™ (2nd dose) = 7, AEFI reaction that occurred from other than fact sheet for COVISHIELD™ (2nd dose) = 0, Total = 7 AEFIs. (n = 3), hypertension (n = 2), gastroesophageal reflux disease (2), hyperthyroidism + hypertension (n = 1), diabetes mellitus (n = 1), and bronchial asthma (n = 1). Most of the AEFIs [62.02% (n = 276)] were observed at the SOC of 'general disorders and administration site conditions' and the least affected SOC was 'blood and lymphatic system disorders' (n = 1). The details of the SOC implicated in AEFIs are presented in Table 5 .

After the causality assessment, out of 433 AEFIs to COVISHIELD TM vaccine, 94.22% (n = 408) of events were categorized to have 'consistent causal association with immunization', which included 342 (78.98%) events of 'vaccine product-related reaction' and 66 (15.24%) events of 'immunization anxiety-related reaction'. Out of 12 AEs following COVAXIN™, 8 (66.66%) events were categorized as 'consistent causal association with immunization' and all of the reactions were 'immunization anxiety-related reactions'. Eleven events following COVISHIELD TM and two events following COVAXIN™ were categorized as having an 'inconsistent causal association with immunization'. The casuality assessment categories are depicted in Figure 2 .

In all, 94.52% of the AEFIs were mild, three events were moderate, and one event was severe. None of the events were categorized as serious in nature. More than half of the study population (57.99%) sought medical attention due to AEs, and among them the majority [91.66%, n = 143)] had telephonic contact with the doctor and the rest (8.44%, n = 13) visited their doctor. None of the events fulfilled the criteria to become a serious event. Data on medical attention were collected, while the AEFI was reported spontaneously, and all of them voluntarily decided to obtain medical attention for their AEFIs. All the study population recovered from their AEs without any sequelae.

Both the vaccines introduced in India had undergone the rigorous, multistage testing process, including phase III clinical trials that involved thousands of subjects to ensure the safety of the vaccines. 8 19 Europe reported the majority of the AEFIs to the global database, contributing to 73% of the total reports followed by 17% from America and 6% from Asia. 19 We observed more AEFIs in the age group of 18-45 years, and an incidence of AEFI occurrence in this age group was 2.62%. We also observed 40% of events following COVID-19 vaccines, in line with that reported in VigiAccess for the age group of 18-44 years. 19 This might be due to the fact that the first groups who received vaccination were health care professionals and frontline workers who majorly belonged to this age group. In total, 71% of females developed AEFIs in this study comparable to 73% of females globally. 19 Also, there were a larger number of reports in the first half of the study duration (n = 159) and fewer reports in the second half (n = 110).

We observed an incidence rate of 3.48% of AEFIs among the study population, whereas the national incidence rate reported was 0.016%. 18 This difference in the incidence rate might be due to the fact that most vaccinators across the country give more preference to vaccinate their beneficiaries and educate them about mild or moderate AEFIs. And health care workers/consumers may not spend their time to report any mild or moderate AEFIs, which were already known. Underreporting is one of the major concerns in the spontaneous reporting method of safety surveillance. However, the study site is a recognized AMC under the Pharmacovigilance Program of India, and the HCWs are aware of the importance of Pharmacovigilance activities. Also, we observed that the incidence rate of COVISHIELD TM is higher when compared with COVAXIN TM . This large difference might be due to the change in the population who received both these vaccines. COVISHIELD TM was received by healthcare workers/frontline workers who were working in the hospital set up, and the beneficiaries were aware of the reporting system of AEs and had taken initiatives to contact the study team, whereas COVAXIN TM was taken majorly by frontline workers who were working outside the hospital setup and citizens who were not aware of the importance of AEFI reporting. Also, the vaccination team explained all the beneficiaries, the possible AEFIs, and management strategies at home. Hence, the reporting rate was less for COVAXIN TM . The incidence rate of AEFIs reported within 30 min was 0.66%, and a similar result of 0.9% incidence was observed in a recent Indian study. 20 However, the overall incidence in this study 20 was as high as 40%, which is much higher than the incidence observed in the current study (3.48%). This might be due to the difference in the study method as the refereed study had followed up their beneficiaries in fixed time intervals for identifying the AEs, and they enrolled a smaller study population compared with our study.

We observed AEFIs, which were not seen in the clinical trials of both COVISHIELD TM and COVAXIN TM , and similar events were seen in the VigiAccess TM . A very less number of the study population with comorbidities developed AEFIs, which shows that the vaccine is safe for beneficiaries with any kind of comorbidities. The SOC implicated majorly in the AEFIs was 'general disorders and administration site conditions', and the same is observed in the global database. We observed less number of events with the SOC of 'blood and lymphatic system disorders' and observed a total of 25,160 events in this SOC in the VigiAccess TM . However, we have not reported any event of blood clots, a majorly discussed rare event globally. 21 Another majorly involved SOC observed in VigiAccess TM was musculoskeletal and connective tissue disorders (n = 209779), and 15.52% of the events were categorized under this SOC in the current study. 19 In all, 94.22% and 66.66% of events, respectively, following COVISHIELD TM and COVAXIN™ were categorized as having a consistent causal association with immunization, out of which 342 (78.98%) events following COVISHIELD TM and all events following COVAXIN TM were classified as vaccine product-related reactions. A total of 3.23% (n = 14) of events following COVISHIELD TM and 16.66% (n = 2) of events following COVAXIN TM were categorized under 'indeterminate' as the temporal relationship was consistent, but there was insufficient definitive evidence for vaccine causing events. These events may be potential signals as these were not present in the fact sheets as well. A total of 13 events were categorized as coincidental as those were caused by something other than the vaccine product, immunization error, or immunization anxiety. In the new causality assessment scale, only reactions that have evidence in published peer-reviewed literature that this vaccine might cause the event if administered correctly are classified as a vaccine product-related reactions. Reactions observed for the first time during post-marketing surveillance were not considered as 'consistent with a causal association with vaccine'. All new serious AEs are labeled as coincidental events 'inconsistent with causal association' or 'unclassifiable', and the association with the vaccine is not acknowledged. This mandates the conduct of systematic postmarketing surveillance studies. 22

As the study followed a spontaneous reporting method, we could not collect the data of all beneficiaries who had comorbidities and did not develop AEFIs. Similarly, we could not calculate the proportion of AEFIs reported in HCWs, vaccine-wise and dose-wise, as complete information was not available with the study team. Both the vaccines described in the study were introduced in two different timelines, which led to the large difference in the number of beneficiaries receiving each of these vaccines.

This study observed a higher incidence rate of AEFIs than the country's overall incidence rate as the study site is an AMC and the HCWs were aware of the vaccine safety activities. None of the events reported were severe or serious, which reiterates that the vaccines used in India are safe and the events will last without any kind of sequelae. Studies of this nature reinforce the need for vigilant monitoring and reporting of AEFIs especially for newly introduced vaccines, as to identify potential signals.

COVID-19: a brief history and treatments in development

COVID-19 and the great Chinese puzzle. The Hindu

WHO declares COVID-19 a pandemic

Impact of COVID-19 pandemic on psychological responses of the general population in India: a nationwide survey

COVID-19 India timeline. The Wire

COVID-19 vaccine development, trials and tribulations

Coronavirus vaccine development: from SARS and MERS to COVID-19

COVID-19): vaccines. World Health Organization

Press Statement by the Drugs Controller General of India (DCGI) on Restricted Emergency approval of COVID-19 virus vaccine

Covishield fact sheet for vaccine recipient approved for restricted use in emergency situation of ChAdOx1 nCoV-19 corona virus vaccine (recombinant)

Fact sheet for vaccine recipients and caregivers

PM to launch Pan India Rollout of COVID-19 Vaccination drive on 16|

India rolls out the world's largest COVID-19 vaccination drive

Coronavirus first phase of vaccination to start on January

lakh Daily Target: what to expect as India vaccinates citizens above

COVID-19 vaccines operational guidelines. Ministry of Health and Family Welfare

Causality assessment of adverse events following immunization user guide for revised WHO classification

Co-WIN winning over COVID-19. Ministry of Health and Family Welfare. government of India

VigiAccessTM

A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers-first results from India

Blood clotting following COVID-19 vaccination

Modernising vaccine surveillance systems to improve detection of rare or poorly defined adverse events

The authors would like to acknowledge the support received from the vaccination team of the COVID-19 vaccination center of the study site. We also thank the administrators and our colleagues for their encouragement throughout the study, which made the data collection and assessment possible.Author contributions JS and MDR were involved in designing the research and getting the necessary approvals required for the study. JS and SBJ were involved in the data collection, data analysis, and preparation of the manuscript. CKB provided the necessary clinical support for the study. CKB, JS, and MDR were also involved in the monitoring of the research and finalization of the manuscript.

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The authors received no financial support for the research, authorship, and/or publication of this article.

https://orcid.org/0000-0002 -4626-8729